CELL SEARCH SYSTEM -CELL BANK- (RIKEN BRC) [RCB1965 : EBC-1]

3289 Yamashita J, Tashiro K, Yoneda S, Kawahara K, Shirakusa T Local increase in polymorphonuclear leukocyte elastase is associated with tumor invasiveness in non-small cell lung cancer. Chest 1996 109:1328-34 PubMed ID: 8625686 DOI: 10.1378/chest.109.5.1328

3287 Takigawa N, Ohnoshi T, Ueoka H, Kiura K, Moritaka T, Tabata M, Segawa Y, Shibayama T, Gemba K, Matsumura T, et al. [In vitro comparison of podophyllotoxin analogues; etoposide, teniposide and NK 611 using human lung cancer cell lines] Gan To Kagaku Ryoho 1993 20:473-7 PubMed ID: 8383949

3288 Takigawa N, Ohnoshi T, Ueoka H, Horiguchi T, Kiura K, Tabata M, Segawa Y, Shibayama T, Genba K, Matsumura T, et al. [Assessment of antitumor activity rhizoxin for human lung cancer cell lines: a potent new drug for drug-resistant lung cancer] Gan To Kagaku Ryoho 1993 20:1221-6 PubMed ID: 8392827

3285 Kitamura M, Shirasawa T, Mitarai T, Muramatsu T, Maruyama N A retinoid responsive cytokine gene, MK, is preferentially expressed in the proximal tubules of the kidney and human tumor cell lines. Am J Pathol 1993 142:425-31 PubMed ID: 8434639

5059 Hiraki S, Miyai M, Seto T, Tamura T, Watanabe Y, Ozawa S, Ikeda H, Nakata Y, Ohnoshi T, Kimura I Establishment of human continuous cell lines from squamous cell, adeno- and small cell carcinoma of the lung and the results of hetero-transplantation Haigan 1982 22(1):53-8

Top

User's Publication

19963 Eguchi H, Yu Y, Matsunaga T, Yoshino Y, Ikari A. Acrolein suppresses anticancer drug-induced toxicity mediated by activating claudin-1 and Nrf2 axis in a spheroid model of human lung squamous cell carcinoma cells Toxicol Lett 2024 392:46-55 PubMed ID: 38142011 DOI: 10.1016/j.toxlet.2023.12.012

21562 Evers A, Krah S, Demir D, Gaa R, Elter D, Schroeter C, Zielonka S, Rasche N, Dotterweich J, Knuehl C, Doerner A. Engineering hydrophobicity and manufacturability for optimized biparatopic antibody-drug conjugates targeting c-MET. MAbs 2024 16(1):2302386 PubMed ID: 38214660 DOI: 10.1080/19420862.2024.2302386

21736 Thu YM, Suzawa K, Tomida S, Ochi K, Tsudaka S, Takatsu F, Date K, Matsuda N, Iwata K, Nakata K, Shien K, Yamamoto H, Okazaki M, Sugimoto S, Toyooka S. PAI-1 mediates acquired resistance to MET-targeted therapy in non-small cell lung cancer. PLoS One 2024 19(5):e0300644 PubMed ID: 38758826 DOI: 10.1371/journal.pone.0300644

19544 Sumitomo R, Menju T, Shimazu Y, Toyazaki T, Chiba N, Miyamoto H, Hirayama Y, Nishikawa S, Tanaka S, Yutaka Y, Yamada Y, Nakajima D, Ohsumi A, Hamaji M, Sato A, Yoshizawa A, Huang CL, Haga H, Date H. M2-like tumor-associated macrophages promote epithelial-mesenchymal transition through the transforming growth factor β/Smad/zinc finger e-box binding homeobox pathway with increased metastatic potential and tumor cell proliferation in lung squamous cell carcinoma Cancer Sci 2023 114(12):4521-4534 PubMed ID: 37806311 DOI: 10.1111/cas.15987

19984 Groothuis PG, Jacobs DCH, Hermens IAT, Damming D, Berentsen K, Mattaar-Hepp E, Stokman MEM, Boekel TV, Rouwette M, van der Vleuten MAJ, Sesink A, Dijcks FA, Coumans RGE, Schouten J, Glaudemans DH, Wijk DV, Blomenröhr M, Kappers WA, Ubink R, van der Lee MMC, Dokter WHA. Preclinical Profile of BYON3521 Predicts an Effective and Safe MET Antibody-Drug Conjugate Mol Cancer Ther 2023 22(6):765-777 PubMed ID: 37042205 DOI: 10.1158/1535-7163.MCT-22-0596

21174 Alburquerque-Bejar JJ, Navajas-Chocarro P, Saigi M, Ferrero-Andres A, Morillas JM, Vilarrubi A, Gomez A, Mate JL, Munoz-Marmol AM, Romero OA, Blecua P, Davalos V, Esteller M, Pros E, Llabata P, Torres-Diz M, Esteve-Codina A, Sanchez-Cespedes M. MYC activation impairs cell-intrinsic IFNγ signaling and confers resistance to anti-PD1/PD-L1 therapy in lung cancer. Cell Rep Med 2023 PubMed ID: 37044092 DOI: 10.1016/j.xcrm.2023.101006

21436 Takatsu F, Suzawa K, Tomida S, Thu YM, Sakaguchi M, Toji T, Ohki M, Tsudaka S, Date K, Matsuda N, Iwata K, Zhu Y, Nakata K, Shien K, Yamamoto H, Nakayama A, Okazaki M, Sugimoto S, Toyooka S. Periostin secreted by cancer-associated fibroblasts promotes cancer progression and drug resistance in non-small cell lung cancer. J Mol Med (Berl) 2023 PubMed ID: 37831111 DOI: 10.1007/s00109-023-02384-7

21505 Sima L, Wang Z, Yu L, Hou Y, Zhao D, Luo B, Liao W, Liu X. Discovery of LAH-1 as potent c-Met inhibitor for the treatment of non-small cell lung cancer. J Enzyme Inhib Med Chem 2023 39(1):2286435 PubMed ID: 38078363 DOI: 10.1080/14756366.2023.2286435

16733 Stern YE, Al-Ghabkari A, Monast A, Fiset B, Aboualizadeh F, Yao Z, Stagljar I, Walsh LA, Duhamel S, Park M. Met-HER3 crosstalk supports proliferation via MPZL3 in MET-amplified cancer cells Cell Mol Life Sci 2022 79(3):178 PubMed ID: 35249128 DOI: 10.1007/s00018-022-04149-w

16830 Sumiya R, Terayama M, Hagiwara T, Nakata K, Sekihara K, Nagasaka S, Miyazaki H, Igari T, Yamada K, Kawamura YI. Loss of GSTO2 contributes to cell growth and mitochondria function via the p38 signaling in lung squamous cell carcinoma Cancer Sci 2022 113(1):195-204 PubMed ID: 34726807 DOI: 10.1111/cas.15189

13332 Hase H, Aoki M, Matsumoto K, Nakai S, Nagata T, Takeda A, Ueda K, Minami K, Kitae K, Jingushi K, Ueda Y, Yamamoto M, Furukawa T, Sato M, Tsujikawa K. Cancer type‑SLCO1B3 promotes epithelial‑mesenchymal transition resulting in the tumour progression of non‑small cell lung cancer. Oncol Rep 2021 PubMed ID: 33155667 DOI: 10.3892/or.2020.7839

20043 Yuan G, Flores NM, Hausmann S, Lofgren SM, Kharchenko V, Angulo-Ibanez M, Sengupta D, Lu X, Czaban I, Azhibek D, Vicent S, Fischle W, Jaremko M, Fang B, Wistuba II, Chua KF, Roth JA, Minna JD, Shao NY, Jaremko Ł, Mazur PK, Gozani O. Elevated NSD3 histone methylation activity drives squamous cell lung cancer. Nature 2021 590(7846):504-508 PubMed ID: 33536620 DOI: 10.1038/s41586-020-03170-y

14789 Chang A, Liu L, Ashby JM, Wu D, Chen Y, O'Neill SS, Huang S, Wang J, Wang G, Cheng D, Tan X, Petty WJ, Pasche BC, Xiang R, Zhang W, Sun P. Recruitment of KMT2C/MLL3 to DNA Damage Sites Mediates DNA Damage Responses and Regulates PARP Inhibitor Sensitivity in Cancer Cancer Res 2021 81(12):3358-3373 PubMed ID: 33853832 DOI: 10.1158/0008-5472.CAN-21-0688

15499 Kosaka A, Yajima Y, Hatayama M, Ikuta K, Sasaki T, Hirai N, Yasuda S, Nagata M, Hayashi R, Harabuchi S, Ohara K, Ohara M, Kumai T, Ishibashi K, Hirata-Nozaki Y, Nagato T, Oikawa K, Harabuchi Y, Celis E, Okumura T, Ohsaki Y, Kobayashi H, Ohkuri T. A stealth antigen SPESP1, which is epigenetically silenced in tumors, is a suitable target for cancer immunotherapy Cancer Sci 2021 112(7):2705-2713 PubMed ID: 34009705 DOI: 10.1111/cas.14973

16228 Joseph M. Gozgit, Melissa M. Vasbinder, Ryan P. Abo, Kaiko Kunii, Kristy G. Kuplast-Barr, Bin Gui, Alvin Z. Lu, Jennifer R. Molina, Elena Minissale, Kerren K. Swinger, Tim J. Wigle, Danielle J. Blackwell, Christina R. Majer, Yue Ren, Mario Niepel, Zacharenia A. Varsamis, Sunaina P. Nayak, Ellen Bamberg, Jan-Rung Mo, W. David Church, Ahmed S.A. Mady, Jeff Song, Luke Utley, Patricia E. Rao, Timothy J. Mitchison, Kevin W. Kuntz, Victoria M. Richon, Heike Keilhack PARP7 negatively regulates the type I interferon response in cancer cells and its inhibition triggers antitumor immunity Cancer Cell 2021 39(9):1214-1226.e10 PubMed ID: 34375612 DOI: 10.1016/j.ccell.2021.06.018

16801 Minegishi K, Dobashi Y, Tsubochi H, Hagiwara K, Ishibashi Y, Nomura S, Nakamura R, Ohmoto Y, Endo S. TFF-1 Functions to Suppress Multiple Phenotypes Associated with Lung Cancer Progression Onco Targets Ther 2021 14:4761-4777 PubMed ID: 34531663 DOI: 10.2147/OTT.S322697

12073 Haruna M, Hirata M, Iwahori K, Kanazawa T, Yamamoto Y, Goto K, Kawashima A, Morimoto-Okazawa A, Funaki S, Shintani Y, Kumanogoh A, Wada H. Docetaxel Upregulates HMGB1 Levels in Non-small Cell Lung Cancer. Biol. Pharm. Bull. 2020 PubMed ID: 32115500 DOI: 10.1248/bpb.b19-00702

13401 Hayashi R, Nagato T, Kumai T, Ohara K, Ohara M, Ohkuri T, Hirata-Nozaki Y, Harabuchi S, Kosaka A, Nagata M, Yajima Y, Yasuda S, Oikawa K, Kono M, Kishibe K, Takahara M, Katada A, Hayashi T, Celis E, Harabuchi Y, Kobayashi H. Expression of placenta-specific 1 and its potential for eliciting anti-tumor helper T-cell responses in head and neck squamous cell carcinoma. Oncoimmunology 2020 PubMed ID: 33457076 DOI: 10.1080/2162402X.2020.1856545

13773 Saigusa D, Motoike IN, Saito S, Zorzi M, Aoki Y, Kitamura H, Suzuki M, Katsuoka F, Ishii H, Kinoshita K, Motohashi H, Yamamoto M. Impacts of NRF2 activation in non-small-cell lung cancer cell lines on extracellular metabolites Cancer Sci 2020 111(2):667-678 PubMed ID: 31828882 DOI: 10.1111/cas.14278

13841 Eguchi R, Wakabayashi I. HDGF enhances VEGF‑dependent angiogenesis and FGF‑2 is a VEGF‑independent angiogenic factor in non‑small cell lung cancer Oncol Rep 2020 44(1):14-28 PubMed ID: 32319650 DOI: 10.3892/or.2020.7580

14799 Zenke FT, Zimmermann A, Sirrenberg C, Dahmen H, Kirkin V, Pehl U, Grombacher T, Wilm C, Fuchss T, Amendt C, Vassilev LT, Blaukat A. Pharmacologic Inhibitor of DNA-PK, M3814, Potentiates Radiotherapy and Regresses Human Tumors in Mouse Models Mol Cancer Ther 2020 19(5):1091-1101. PubMed ID: 32220971 DOI: 10.1158/1535-7163.MCT-19-0734

4183 Ohara K, Ohkuri T, Kumai T, Nagato T, Nozaki Y, Ishibashi K, Kosaka A, Nagata M, Harabuchi S, Ohara M, Oikawa K, Aoki N, Harabuchi Y, Celis E, Kobayashi H. Targeting phosphorylated p53 to elicit tumor-reactive T helper responses against head and neck squamous cell carcinoma. Oncoimmunology 2018 PubMed ID: 30510853 DOI: 10.1080/2162402X.2018.1466771

4475 Iijima M, Gombodorj N, Tachibana Y, Tachibana K, Yokobori T, Honma K, Nakano T, Asao T, Kuwahara R, Aoyama K, Yasuda H, Kelly M, Kuwano H, Yamanouchi D. Development of single nanometer-sized ultrafine oxygen bubbles to overcome the hypoxia-induced resistance to radiation therapy via the suppression of hypoxia-inducible factor‑1α. Int. J. Oncol. 2018 52(3):679-686 PubMed ID: 29393397 DOI: 10.3892/ijo.2018.4248

14222 Horie M, Kaczkowski B, Ohshima M, Matsuzaki H, Noguchi S, Mikami Y, Lizio M, Itoh M, Kawaji H, Lassmann T, Carninci P, Hayashizaki Y, Forrest ARR, Takai D, Yamaguchi Y, Micke P, Saito A, Nagase T. Integrative CAGE and DNA Methylation Profiling Identify Epigenetically Regulated Genes in NSCLC Mol Cancer Res 2017 15(10):1354-1365 PubMed ID: 28698358 DOI: 10.1158/1541-7786.MCR-17-0191

14238 Ozono K, Ohishi Y, Onishi H, Nakamura K, Motoshita J, Kato M, Nakanishi R, Nakamura M, Oda Y. Brain-derived neurotrophic factor/tropomyosin-related kinase B signaling pathway contributes to the aggressive behavior of lung squamous cell carcinoma Lab Invest 2017 97(11):1332-1342 PubMed ID: 28604655 DOI: 10.1038/labinvest.2017.45

14945 Togayachi A, Iwaki J, Kaji H, Matsuzaki H, Kuno A, Hirao Y, Nomura M, Noguchi M, Ikehara Y, Narimatsu H. Glycobiomarker, Fucosylated Short-Form Secretogranin III Levels Are Increased in Serum of Patients with Small Cell Lung Carcinoma. J Proteome Res 2017 16:4495-4505 PubMed ID: 28949141 DOI: 10.1021/acs.jproteome.7b00484

9887 Ye X, Zhou Q, Matsumoto Y, Moriyama M, Kageyama S, Komatsu M, Satoh S, Tsuchida M, Saijo Y. Inhibition of Glutaminolysis Inhibits Cell Growth via Down-regulating Mtorc1 Signaling in Lung Squamous Cell Carcinoma. Anticancer Res. 2016 36:6021-6029 PubMed ID: 27793929 DOI: 10.21873/anticanres.11191

9977 Sellmann C, Doerner A, Knuehl C, Rasche N, Sood V, Krah S, Rhiel L, Messemer A, Wesolowski J, Schuette M, Becker S, Toleikis L, Kolmar H, Hock B. Balancing Selectivity and Efficacy of Bispecific Epidermal Growth Factor Receptor (EGFR) × c-MET Antibodies and Antibody-Drug Conjugates. J. Biol. Chem. 2016 291:25106-25119 PubMed ID: 27694443 DOI: 10.1074/jbc.M116.753491

12612 Yonesaka K, Hirotani K, Kawakami H, Takeda M, Kaneda H, Sakai K, Okamoto I, Nishio K, Jänne PA, Nakagawa K. Anti-HER3 monoclonal antibody patritumab sensitizes refractory non-small cell lung cancer to the epidermal growth factor receptor inhibitor erlotinib Oncogene 2016 35(7):878-86 PubMed ID: 25961915 DOI: 10.1038/onc.2015.142

18948 Harada M, Kotake Y, Ohhata T, Kitagawa K, Niida H, Matsuura S, Funai K, Sugimura H, Suda T, Kitagawa M. YB-1 promotes transcription of cyclin D1 in human non-small-cell lung cancers Genes Cells 2014 19(6):504-16 PubMed ID: 24774443 DOI: 10.1111/gtc.12150

15909 Fang WT, Fan CC, Li SM, Jang TH, Lin HP, Shih NY, Chen CH, Wang TY, Huang SF, Lee AY, Liu YL, Tsai FY, Huang CT, Yang SJ, Yen LJ, Chuu CP, Chen CY, Hsiung CA, Chang JY, Wang LH, Chang IS, Jiang SS. Downregulation of a putative tumor suppressor BMP4 by SOX2 promotes growth of lung squamous cell carcinoma Int J Cancer 2014 135(4):809-19 PubMed ID: 24477565 DOI: 10.1002/ijc.28734

5843 Bladt F, Faden B, Friese-Hamim M, Knuehl C, Wilm C, Fittschen C, Grädler U, Meyring M, Dorsch D, Jaehrling F, Pehl U, Stieber F, Schadt O, Blaukat A. EMD 1214063 and EMD 1204831 constitute a new class of potent and highly selective c-Met inhibitors. Clin Cancer Res 2013 19(11):2941-51 PubMed ID: 23553846 DOI: 10.1158/1078-0432.CCR-12-3247

13951 Oshita H, Nishino R, Takano A, Fujitomo T, Aragaki M, Kato T, Akiyama H, Tsuchiya E, Kohno N, Nakamura Y, Daigo Y. RASEF is a novel diagnostic biomarker and a therapeutic target for lung cancer Mol Cancer Res 2013 11(8):937-51 PubMed ID: 23686708 DOI: 10.1158/1541-7786.MCR-12-0685-T

17162 Kimura M, Naito H, Tojo T, Itaya-Hironaka A, Dohi Y, Yoshimura M, Nakagawara K, Takasawa S, Taniguchi S. REG Iα gene expression is linked with the poor prognosis of lung adenocarcinoma and squamous cell carcinoma patients via discrete mechanisms Oncol Rep 2013 30(6):2625-31 PubMed ID: 24065141 DOI: 10.3892/or.2013.2739

19029 Kanamori-Katayama M, Kaiho A, Ishizu Y, Okamura-Oho Y, Hino O, Abe M, Kishimoto T, Sekihara H, Nakamura Y, Suzuki H, Forrest AR, Hayashizaki Y. LRRN4 and UPK3B are markers of primary mesothelial cells PLoS One 2011 6(10):e25391 PubMed ID: 21984916 DOI: 10.1371/journal.pone.0025391

16553 Hayashi S, Kumai T, Matsuda Y, Aoki N, Sato K, Kimura S, Kitada M, Tateno M, Celis E, Kobayashi H. Six-transmembrane epithelial antigen of the prostate and enhancer of zeste homolog 2 as immunotherapeutic targets for lung cancer J Transl Med 2011 9:191 PubMed ID: 22053850 DOI: 10.1186/1479-5876-9-191

16149 Kayamori K, Sakamoto K, Nakashima T, Takayanagi H, Morita K, Omura K, Nguyen ST, Miki Y, Iimura T, Himeno A, Akashi T, Yamada-Okabe H, Ogata E, Yamaguchi A. Roles of interleukin-6 and parathyroid hormone-related peptide in osteoclast formation associated with oral cancers: significance of interleukin-6 synthesized by stromal cells in response to cancer cells Am J Pathol 2010 176(2):968-80 PubMed ID: 20035059 DOI: 10.2353/ajpath.2010.090299

6410 Danjoh I, Sone H, Noda N, Iimura E, Nagayoshi M, Saijo K, Hiroyama T, Nakamura Y. Is parainfluenza virus a threatening virus for human cancer cell lines? Hum Cell 2009 22(3):81-4 PubMed ID: 19624309 DOI: 10.1111/j.1749-0774.2009.00071.x

18311 Mitsuoka K, Miyoshi S, Kato Y, Murakami Y, Utsumi R, Kubo Y, Noda A, Nakamura Y, Nishimura S, Tsuji A. Cancer detection using a PET tracer, 11C-glycylsarcosine, targeted to H+/peptide transporter J Nucl Med 2008 49(4):615-22 PubMed ID: 18344442 DOI: 10.2967/jnumed.107.048231

17238 Matsuda Y, Yamamoto T, Kudo M, Kawahara K, Kawamoto M, Nakajima Y, Koizumi K, Nakazawa N, Ishiwata T, Naito Z. Expression and roles of lumican in lung adenocarcinoma and squamous cell carcinoma Int J Oncol 2008 33(6):1177-85 PubMed ID: 19020750

19312 Yabuta N, Onda H, Watanabe M, Yoshioka N, Nagamori I, Funatsu T, Toji S, Tamai K, Nojima H. Isolation and characterization of the TIGA genes, whose transcripts are induced by growth arrest Nucleic Acids Res 2006 34(17):4878-92. PubMed ID: 16973895 DOI: 10.1093/nar/gkl651

16648 Konishi J, Yamazaki K, Yokouchi H, Shinagawa N, Iwabuchi K, Nishimura M. The characteristics of human NKT cells in lung cancer--CD1d independent cytotoxicity against lung cancer cells by NKT cells and decreased human NKT cell response in lung cancer patients Hum Immunol 2004 65(11):1377-88 PubMed ID: 15556688 DOI: 10.1016/j.humimm.2004.09.003

15111 Togayachi A, Akashima T, Ookubo R, Kudo T, Nishihara S, Iwasaki H, Natsume A, Mio H, Inokuchi J, Irimura T, Sasaki K, Narimatsu H. Molecular cloning and characterization of UDP-GlcNAc:lactosylceramide beta 1,3-N-acetylglucosaminyltransferase (beta 3Gn-T5), an essential enzyme for the expression of HNK-1 and Lewis X epitopes on glycolipids J Biol Chem 2001 276(25):22032-40 PubMed ID: 11283017 DOI: 10.1074/jbc.M011369200

1896 Bando T, Fujimura M, Kasahara K, Ueno T, Matsuda T. Selective beta2-adrenoceptor agonist enhances sensitivity to cisplatin in non-small cell lung cancer cell line Oncol Rep 2000 7(1):49-52 PubMed ID: 10601590 DOI: 10.3892/or.7.1.49

18075 Bando T, Fujimura M, Kasahara K, Shibata K, Shirasaki H, Heki U, Iwasa K, Ueda A, Tomikawa S, Matsuda T. Stimulation of beta-adrenoceptor enhances sensitivity to cisplatin in non-small cell lung cancer cell lines Int J Oncol 1997 10(6):1197-201 PubMed ID: 21533504 DOI: 10.3892/ijo.10.6.1197